Price T Rowe Associates Inc. MD Acquires 4,229 Shares of Certara, Inc. (NASDAQ:CERT)

Price T Rowe Associates Inc. MD grew its holdings in Certara, Inc. (NASDAQ:CERT) by 6.3% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 71,494 shares of the company’s stock after acquiring an additional 4,229 shares during the quarter. Price T Rowe Associates Inc. MD’s holdings in Certara were worth $762,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of CERT. Barclays PLC increased its stake in Certara by 198.3% during the 3rd quarter. Barclays PLC now owns 70,525 shares of the company’s stock worth $825,000 after purchasing an additional 46,880 shares in the last quarter. GAMMA Investing LLC lifted its stake in Certara by 442.2% in the fourth quarter. GAMMA Investing LLC now owns 8,421 shares of the company’s stock valued at $90,000 after buying an additional 6,868 shares in the last quarter. Kopion Asset Management LLC boosted its holdings in shares of Certara by 46.0% in the fourth quarter. Kopion Asset Management LLC now owns 555,643 shares of the company’s stock valued at $5,918,000 after buying an additional 175,005 shares during the period. Blue Trust Inc. increased its position in shares of Certara by 20.9% during the fourth quarter. Blue Trust Inc. now owns 4,747 shares of the company’s stock worth $56,000 after acquiring an additional 822 shares in the last quarter. Finally, KBC Group NV raised its holdings in shares of Certara by 64.1% during the fourth quarter. KBC Group NV now owns 7,998 shares of the company’s stock worth $85,000 after acquiring an additional 3,125 shares during the period. 73.96% of the stock is currently owned by institutional investors.

Certara Price Performance

NASDAQ:CERT opened at $11.98 on Monday. The stock has a market capitalization of $1.94 billion, a PE ratio of -59.90, a P/E/G ratio of 9.29 and a beta of 1.57. Certara, Inc. has a 1-year low of $8.64 and a 1-year high of $17.76. The firm has a fifty day simple moving average of $11.67 and a 200 day simple moving average of $11.69. The company has a current ratio of 2.86, a quick ratio of 2.86 and a debt-to-equity ratio of 0.28.

Certara (NASDAQ:CERT) last announced its quarterly earnings data on Monday, May 5th. The company reported $0.14 EPS for the quarter, beating analysts’ consensus estimates of $0.10 by $0.04. The company had revenue of $106.00 million during the quarter, compared to the consensus estimate of $104.44 million. Certara had a negative net margin of 8.34% and a positive return on equity of 3.43%. The company’s quarterly revenue was up 9.7% on a year-over-year basis. During the same quarter last year, the firm posted $0.10 EPS. On average, research analysts expect that Certara, Inc. will post 0.28 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

CERT has been the subject of a number of research analyst reports. Robert W. Baird upped their target price on shares of Certara from $9.00 to $13.00 and gave the stock a “neutral” rating in a research note on Friday, April 11th. JMP Securities reaffirmed a “market perform” rating on shares of Certara in a research report on Tuesday, May 6th. TD Cowen started coverage on Certara in a report on Thursday, February 27th. They set a “buy” rating and a $16.00 price objective for the company. William Blair restated a “market perform” rating on shares of Certara in a research note on Thursday, February 27th. Finally, Barclays raised Certara from an “equal weight” rating to an “overweight” rating and upped their price target for the stock from $11.00 to $14.00 in a research report on Thursday. Three analysts have rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $15.67.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.